Pharmaceuticals & Biotech/Lifesciences
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development
Mar 21 2023
Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech’s treatment of Rett syndrome
Mar 16 2023
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| ACW | $0.07 | $0.16 | $0.04 |
$0.15 |
||
| AFP | AFT PHARMACEUTICALS LIMITED | $3.20 | $3.77 | $2.90 |
$3.16 |
|
| ANP | ANTISENSE THERAPEUTICS LIMITED | $0.09 | $0.15 | $0.07 |
$0.26 |
|
| ARX | AROA BIOSURGERY LIMITED | $1.04 | $1.25 | $0.63 |
$1.51 |
|
| AVH | AVITA MEDICAL INC | $3.92 | $4.41 | $0.00 |
$5.217 |
|
| CSL | CSL LIMITED | $288.94 | $xx.xx | $xx.xx | xx.x | xx.xx |
| GSS | GENETIC SIGNATURES LIMITED | $0.78 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMM | IMMUTEP LIMITED | $0.26 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMU | IMMUTEP LIMITED | $0.13 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MAP | MICROBA LIFE SCIENCES LIMITED | $0.34 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MDC | MEDLAB CLINICAL LIMITED | $6.60 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MSB | MESOBLAST LIMITED | $0.94 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MVP | MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED | $1.16 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MYX | MAYNE PHARMA GROUP LIMITED | $3.50 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NEU | MAYNE PHARMA GROUP LIMITED | $13.15 | $xx.xx | $xx.xx | xx.x | xx.xx |
| OCC | MAYNE PHARMA GROUP LIMITED | $0.37 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PAR | PARADIGM BIOPHARMACEUTICALS LIMITED | $1.36 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PBP | PROBIOTEC LIMITED | $2.40 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PNV | POLYNOVO LIMITED | $1.81 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PXS | POLYNOVO LIMITED | $0.05 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SPL | STARPHARMA HOLDINGS LIMITED | $0.48 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TLX | TELIX PHARMACEUTICALS LIMITED | $7.03 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TRP | TISSUE REPAIR LIMITED | $0.20 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
Dr Boreham’s Crucible: Actinogen Medical
Nov 30 2022
Actinogen Medical is a biotech with a potentially “gazillion” dollar opportunity in its Alzheimer’s drug
Dr Boreham’s Crucible: Qbiotics Group
Nov 09 2022
Having brought a canine cancer treatment to market, Qbiotic’s focus has returned to treating two-legged cancers including melanoma and other difficult-to-treat cancers
Dr Boreham’s Crucible: Pharmaxis
Oct 05 2022
Pharmaxis might be two clinical studies away from rehabilitation, reports Tim Boreham
Brokers Review Prospects For CSL
Sep 30 2022
Brokers remain generally upbeat on CSL and focus upon the earnings contribution from the Vifor Pharma acquisition
Dr Boreham’s Crucible: Inoviq Ltd
Sep 19 2022
Tim Boreham digs deep into the evolving world of cancer diagnostics, highlighting the newly named Inoviq Ltd
CSL: Offering Buying Opportunity
Sep 13 2022
Michael Gable of Fairmont Equities notes price action suggests CSL is a buying opportunity, and more so on a breakout
Dr Boreham’s Crucible: Vaxxas Pty Ltd
Sep 07 2022
Vaxxas is still unlisted, but worth highlighting as yet another Australian success story looks to be unfolding, reports Tim Boreham
Dr Boreham’s Crucible: Telix Pharmaceuticals
Aug 22 2022
Telix Pharmaceuticals’ prostate cancer imaging product Illucix is quickly conquering the USA, but management at the firm has (much) higher ambitions
Dr Boreham’s Crucible: Orthocell
Jul 26 2022
Micro-cap biotech Orthocell is aiming to emulate the successful growth story of Polynovo, nowadays capitalised at $1.1bn
CSL: Buy Trigger Ahead
Apr 26 2022
Michael Gable of Fairmont Equities notes that after two years in the lockdown doldrums, CSL is getting ready to break out
Latest News
| 1 |
The Golden Age Of Critical Materials2:33 PM - Commodities |
| 2 |
Undeterred Premier Plans Ongoing Expansion2:14 PM - Australia |
| 3 |
Uranium Week: Deficit Ahead10:57 AM - Weekly Reports |
| 4 |
S&P500: Looking Bullish10:28 AM - Technicals |
| 5 |
Helloworld Turnaround Now Includes Europe10:01 AM - Small Caps |
